Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer.
作者信息
Lambertini Matteo, Partridge Ann H
机构信息
Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
出版信息
J Natl Cancer Inst. 2021 Oct 1;113(10):1274-1276. doi: 10.1093/jnci/djab066.
Abstract
摘要
相似文献
1
Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer.无环磷酰胺辅助化疗对预防年轻乳腺癌女性过早卵巢功能不全和不孕的潜在作用
J Natl Cancer Inst. 2021 Oct 1;113(10):1274-1276. doi: 10.1093/jnci/djab066.
2
[Premature ovarian failure after chemotherapy for breast cancer].[乳腺癌化疗后卵巢早衰]
Bull Cancer. 2008 Apr;95(4):403-12. doi: 10.1684/bdc.2008.0616.
3
Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.乳腺癌辅助化疗与卵巢早衰及体成分改变。
Menopause. 2011 Nov;18(11):1244-8. doi: 10.1097/gme.0b013e31821b849b.
4
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.促性腺激素释放激素类似物曲普瑞林对乳腺癌绝经前妇女化疗诱导早绝经发生的影响：一项随机试验。
JAMA. 2011 Jul 20;306(3):269-76. doi: 10.1001/jama.2011.991.
5
Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.促性腺激素释放激素激动剂在年轻乳腺癌患者生育力保存中的应用：获益仍不确定。
Ann Oncol. 2013 Sep;24(9):2224-35. doi: 10.1093/annonc/mdt196. Epub 2013 May 24.
6
A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.一项评估促性腺激素拮抗剂西曲瑞克在化疗期间保护卵巢功能作用的试点研究。
Aust N Z J Obstet Gynaecol. 2011 Oct;51(5):452-4. doi: 10.1111/j.1479-828X.2011.01346.x. Epub 2011 Aug 2.
7
Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?GnRH激动剂对年轻乳腺癌患者卵巢功能的保护作用：是否会影响辅助化疗的效果？
Breast. 2014 Oct;23(5):670-5. doi: 10.1016/j.breast.2014.07.005. Epub 2014 Jul 31.
8
The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.绝经前乳腺癌患者的更年期症状风险和当前的药物预防策略。
Expert Opin Drug Saf. 2021 Oct;20(10):1163-1175. doi: 10.1080/14740338.2021.1926980. Epub 2021 May 17.
9
Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.促性腺激素释放激素激动剂在癌症化疗中对卵巢的保护作用：系统评价和荟萃分析。
Ultrasound Obstet Gynecol. 2018 Jan;51(1):77-86. doi: 10.1002/uog.18934. Epub 2017 Dec 1.
10
Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).戈舍瑞林在绝经前早期乳腺癌（EBC）女性辅助化疗期间对卵巢的保护作用。
Breast Cancer Res Treat. 2008 Aug;110(3):411-6. doi: 10.1007/s10549-007-9745-y. Epub 2007 Sep 13.
引用本文的文献
1
Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases.基于嵌合抗原受体的自身免疫性疾病免疫治疗研究进展
Hum Vaccin Immunother. 2025 Dec;21(1):2538350. doi: 10.1080/21645515.2025.2538350. Epub 2025 Aug 1.
2
Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review.青少年和年轻成年乳腺癌患者新辅助治疗中生育力保护与治疗效果的平衡：一项叙述性综述
Curr Oncol Rep. 2024 Dec;26(12):1563-1574. doi: 10.1007/s11912-024-01615-5. Epub 2024 Nov 5.
3
hUMSCs restore ovarian function in POI mice by regulating GSK3β-mediated mitochondrial dynamic imbalances in theca cells.hUMSCs 通过调节颗粒细胞中 GSK3β 介导的线粒体动态失衡来恢复 POI 小鼠的卵巢功能。
Sci Rep. 2024 Aug 16;14(1):19008. doi: 10.1038/s41598-024-69381-9.
4
Azilsartan as a preventive agent against cyclophosphamide-induced testicular injury in male rats.阿齐沙坦作为雄性大鼠环磷酰胺诱导的睾丸损伤的预防剂。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):979-990. doi: 10.1007/s00210-024-03339-6. Epub 2024 Aug 2.
5
Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants.卵巢早衰：氧化应激作用及抗氧化剂应用的综述
Front Endocrinol (Lausanne). 2023 Aug 1;14:1172481. doi: 10.3389/fendo.2023.1172481. eCollection 2023.
6
Preventive Electroacupuncture Alleviates Oxidative Stress and Inflammation via Keap1/Nrf2/HO-1 Pathway in Rats with Cyclophosphamide-Induced Premature Ovarian Insufficiency.电针对环磷酰胺诱导的卵巢早衰大鼠氧化应激和炎症的防治作用及其机制研究。
Biomed Res Int. 2022 Aug 25;2022:6718592. doi: 10.1155/2022/6718592. eCollection 2022.
7
How to Protect Ovarian Function before and during Chemotherapy?如何在化疗前及化疗期间保护卵巢功能？
J Clin Med. 2021 Sep 16;10(18):4192. doi: 10.3390/jcm10184192.
本文引用的文献
1
Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.环磷酰胺免费辅助化疗对年轻乳腺癌女性的卵巢保护作用：一项随机 3 期试验。
J Natl Cancer Inst. 2021 Oct 1;113(10):1352-1359. doi: 10.1093/jnci/djab065.
2
ESHRE guideline: female fertility preservation.欧洲人类生殖与胚胎学会指南：女性生育力保存
Hum Reprod Open. 2020 Nov 14;2020(4):hoaa052. doi: 10.1093/hropen/hoaa052. eCollection 2020.
3
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines.青春期后癌症患者的生育力保存及治疗后妊娠：ESMO临床实践指南
Ann Oncol. 2020 Dec;31(12):1664-1678. doi: 10.1016/j.annonc.2020.09.006. Epub 2020 Sep 22.
4
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.根据免疫组化定义的管腔亚型，激素受体阳性/HER2 阴性早期乳腺癌患者密集辅助化疗的效果：GIM2 试验的探索性分析。
Eur J Cancer. 2020 Sep;136:43-51. doi: 10.1016/j.ejca.2020.05.007. Epub 2020 Jul 4.
5
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).ESO-ESMO 4 版年轻女性乳腺癌国际共识指南（BCY4）。
Ann Oncol. 2020 Jun;31(6):674-696. doi: 10.1016/j.annonc.2020.03.284. Epub 2020 Mar 19.
6
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial).TBCRC 031：新辅助顺铂与多柔比星-环磷酰胺治疗HER2阴性乳腺癌胚系携带者的随机II期研究（INFORM试验）
J Clin Oncol. 2020 May 10;38(14):1539-1548. doi: 10.1200/JCO.19.03292. Epub 2020 Feb 25.
7
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.改善激素受体阳性乳腺癌绝经前女性的辅助内分泌治疗方案调整
J Clin Oncol. 2020 Apr 20;38(12):1258-1267. doi: 10.1200/JCO.19.02242. Epub 2019 Oct 16.
8
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.添加卵巢抑制到他莫昔芬治疗绝经前乳腺癌的随机 III 期试验。
J Clin Oncol. 2020 Feb 10;38(5):434-443. doi: 10.1200/JCO.19.00126. Epub 2019 Sep 16.
9
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.增加化疗剂量强度：通过更频繁的给药或序贯方案在 26 项随机试验中 37 298 例早期乳腺癌患者的个体水平荟萃分析。
Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8.
10
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.蒽环类和紫杉类化疗与多西他赛和环磷酰胺在 HER2 阴性乳腺癌患者辅助治疗中的比较：一项随机对照试验的系统评价和荟萃分析。
Breast Cancer Res Treat. 2019 Feb;174(1):27-37. doi: 10.1007/s10549-018-5055-9. Epub 2018 Nov 21.
Zotero 插件